Investors Chronicle 2000 Dan Oakey - Abstracts

Title	Subject	Authors
Investors Chronicle 2000 Dan Oakey
Bourse merger to help Sid.(plan to merge London and Frankfurt stock exchanges)	Business	Dan Oakey
Bridging the gap.(links between Copenhagen and Stockholm stock exchanges)	Business	Dan Oakey
Drug money.(prospects for selected biotech companies and their products)	Business	Dan Oakey
European alliance.(development of Euro.nm alliance)	Business	Dan Oakey
Exchange fudges on costs.(London Stock Exchange dealing costs; includes related notes)	Business	Dan Oakey
Glaxo faces drug blow.(Glaxo may face condition relating to drug to have SmithKline Beecham merger approved)	Business	Dan Oakey
Healthy Glaxo SmithKline creates a gene giant.(merger between Glaxo Wellcome and SmithKline Beecham)	Business	Dan Oakey
iX could spell disaster for smaller companies.(impact of planned merger of Frankfurt and London stock exchanges)	Business	Dan Oakey, Nick Rome
Just what the doctor didn't order.(problems facing Scotia)	Business	Dan Oakey
Look further afield.(investing in European blue chip companies; includes related articles and related statistical tables)(Cover Story)	Business	Dan Oakey
LSE/Euronext merger answers consolidation conundrum.(role of London Stock Exchange in consolidation in sector)	Business	Dan Oakey
Oil price volatility here to stay.(likelihood for continued volatility of petroleum prices)	Business	Dan Oakey, Chris Dillow, Joe Thomas
Race against time.(Easdaq should benefit from technolgical developments)	Business	Dan Oakey
Ring in the new.(developments affecting investors in 2000)	Business	Dan Oakey

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.